Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

An IDMC review of unblinded interim data was positive and advised that the trials continue as planned, with time to first relapse up to 72 weeks as the primary end point.



Phase 3 ENSURE Program of Vidofludimus Calcium Continues Following Positive Futility Analysis

With the positive recommendation, it marks a key step toward eplontersen’s availability in Europe as a treatment for ATTR polyneuropathy.

Eplontersen Gains Positive CHMP Approval Recommendation for ATTR Polyneuropathy

The 2024 revisions to the McDonald diagnostic criteria for multiple sclerosis (MS) mark a significant advancement in the early detection and diagnosis of the disease, with new biomarkers and a broadened scope that may lead to earlier intervention and improved patient outcomes.

Revised McDonald Diagnostic Criteria Signals New Era in Multiple Sclerosis Treatment

Constantine Farmakidis, MD, an associate professor of neurology at the University of Kansas Medical Center, provided clinical commentary on a subanalysis of a phase 3 study assessing nipocalimab, an investigational agent, in generalized myasthenia gravis.

Understanding Nipocalimab’s Impact on Myasthenia Gravis Using MG-ADL

Associate Professor of Neurology, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; staff neurologist, Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic

, has been with the team since October 2019. Follow him on Twitter 

Videos

Beyond the Guidelines: Monitoring and Defining SMA Progression

In this segment, the panel discussed adult-onset 5q spinal muscular atrophy (SMA), highlighting its frequent underdiagnosis and subtle symptoms such as cramps, fasciculations, and sports intolerance.

Adult-Onset SMA: Diagnosis and Best Practices for Clinicians

The discussion highlighted the need for national or local protocols, insurance approvals, and close collaboration with families to optimize patient outcomes.

Optimizing Treatment Access in SMA: Navigating Timing and Outcomes

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

Neurology Comic: Low-Res Memory